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Abstract
Carcinoma-associated fibroblasts (CAFs) influence the behaviour of cancer cells but the roles of microRNAs in
this interaction are unknown. We report microRNAs that are differentially expressed between breast normal
fibroblasts and CAFs of oestrogen receptor-positive cancers, and explore the influences of one of these, miR-26b,
on breast cancer biology. We identified differentially expressed microRNAs by expression profiling of clinical
samples and a tissue culture model: miR-26b was the most highly deregulated microRNA. Using qPCR, miR-26b
was confirmed as down-regulated in fibroblasts from 15 of 18 further breast cancers. Next, we examined
whether manipulation of miR-26b expression changed breast fibroblast behaviour. Reduced miR-26b expression
caused fibroblast migration and invasion to increase by up to three-fold in scratch-closure and trans-well assays.
Furthermore, in co-culture with MCF7 breast cancer epithelial cells, fibroblasts with reduced miR-26b expression
enhanced both MCF7 migration in trans-well assays and MCF7 invasion from three-dimensional spheroids by up
to five-fold. Mass spectrometry was used to identify expression changes associated with the reduction of miR-26b
expression in fibroblasts. Pathway analyses of differentially expressed proteins revealed that glycolysis/TCA cycle
and cytoskeletal regulation by Rho GTPases are downstream of miR-26b. In addition, three novel miR-26b targets
were identified (TNKS1BP1, CPSF7, COL12A1) and the expression of each in cancer stroma was shown to be
significantly associated with breast cancer recurrence. MiR-26b in breast CAFs is a potent regulator of cancer
behaviour in oestrogen receptor-positive cancers, and we have identified key genes and molecular pathways that
act downstream of miR-26b in CAFs.
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Breast cancer tissue consists of malignant epithelial
cells and various other cell types collectively known
as tumour stroma [1]. It is well established that
tumour stroma plays critical roles in controlling
breast cancer epithelial cell behaviour, and therefore
in defining cancer outcomes [2,3]. Tumour stroma
includes fibroblasts, inflammatory cells, adipocytes,
and blood and lymph vessels [1], but the fibroblasts
are typically most abundant and have consequently
attracted most attention [4]. Gene expression profiles
of these carcinoma-associated fibroblasts (CAFs) differ
substantially from their normal tissue counterparts [5],
although considerable heterogeneity is evident within
CAF populations [6,7]. Studies have identified specific
molecules, such as transforming growth factor β, hep-
atocyte growth factor [8], stromal cell-derived factor-1
[3,6] and phosphatase and tensin homologue [9], that
are expressed by CAFs and regulate carcinoma cell
behaviour, typically leading to enhanced tumouri-
genicity. Studies have also identified gene regulatory
events that are responsible for the deregulation of such
molecules in CAFs, including changes in promoter
methylation [10], the activity of key transcription
factors [11], and even—controversially—somatic
mutations in critical signalling molecules [12].
However, the contributions of microRNAs (miR-
NAs) to gene deregulation in CAFs are virtually
unknown.
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
MiR-26b in breast cancer CAFs 389
MiRNAs are a class of more than 1000 non-coding
RNAs that regulate the expression of up to 60%
of genes [13]. They act by binding to mRNAs,
usually within 3′ untranslated regions, causing post-
transcriptional down-regulation of protein expression
by translational repression and/or mRNA desta-
bilization [14]. Many studies have demonstrated
deregulation of specific miRNAs in breast cancer
and the potential functional consequences within
epithelial cancer cells [15]. Thus, specific miRNAs
can themselves be regarded as ‘tumour suppressors’
or ‘oncogenes’. Examples include miR-10a [16], miR-
373 [17], and miR-21 [18], which act as regulators of
growth, invasion, and metastasis. Interestingly, there is
some evidence that miR-21, which is up-regulated in
breast cancers and was assumed to be functional within
epithelial cells, is in fact predominantly expressed in
fibroblasts [19]. Very recently, attention has been given
to miRNA roles in the fibroblasts of epithelial cancers,
with the first report profiling miRNA expression
differences between CAFs and normal fibroblasts
(NFs) [20]. We examined these differences in great
detail and investigated the functional impacts on CAFs
of the most consistently deregulated miRNA that we
identified, miR-26b.
Materials and methods
Ethics, tissue, and laser micro-dissection (LMD)
Ethical approval was obtained (Leeds East REC
06/Q1206/180). LMD was performed using a
Zeiss/PALM Microscope (Oberkochen, Germany)
from formalin-fixed/paraffin-embedded tissue as
described in the Supplementary materials and meth-
ods. CAFs were defined as fibroblasts present within
tumour masses (as in refs 21 and 22), and less than
2 mm from tumour cells, while NFs were defined
by their association with normal epithelium more
than 1 cm outside tumour masses. Areas selected
were devoid of visible cells other than target cell
types. SMA staining [mouse monoclonal; M851
(Dako, Glostrup, Denmark), 1 : 1000] was performed
using an IntelliPATH automated stainer (Menarini,
Florence, Italy) and the manufacturer’s standard
conditions.
Tissue culture, transfection, transduction, and
functional assays
MCF7 and HB2 cells were obtained from the European
Collection of Cell Cultures. Stable GFP expression was
conferred by pTH-GFPa [23], a selectable GFP expres-
sion vector. MCF7 cells that stably express firefly
luciferase were obtained from Cell Biolabs (San Diego,
CA, USA; #AKR-234). Primary fibroblasts were
isolated from breast surgical samples [24] and immor-
talized by hTERT retroviral transduction as described
previously [25]. Reverse transfection of pre-/anti-miR
(Ambion, Carlsbad, CA, USA) and/or plasmids
was performed using HiPerFect (Qiagen, Hilden,
Germany). Stable miR-26b/control ‘knock-down’ was
performed using pmiRZIP lentiviral vectors (System
Biosciences, Mountain View, USA). Assays for cell
viability, cell cycle, apoptosis, migration, and invasion
were performed as described previously [16,26]. Flow-
cytometry and fluorescence-activated cell sorting were
performed on LSRII (BD Biosciences, Franklin Lakes,
NJ, USA) and MoFlo (Dako) machines, respectively.
Spheroid invasion assays were carried out using
modifications of a previously described method [27].
Spheroids were formalin-fixed/paraffin-embedded,
and 5 µm sections stained with haematoxylin/eosin,
or treated for immunohistochemistry (rabbit anti-
cytokeratin, Ab9377; Abcam, Cambridge, UK; see ref
28) as above. Dual luciferase assays and pmiRGLO
reporter were used (Promega, Fitchburg, WI, USA).
Details may be found in the Supplementary materials
and methods.
RNA extraction, quantitative PCR (qPCR), and
microarray analyses
RecoverAll Total Nucleic Acid Isolation for FFPE
(Ambion) was used for RNA extraction from FFPE.
MirVana miRNA Isolation (Ambion) and RNeasy
(Qiagen) were used for extraction from cell lines of
miRNA and mRNA, respectively. qPCR analyses were
performed on 7500/7900HT machines in triplicate
with Taqman assays (Life Technologies, Carlsbad,
CA, USA). Microarray analyses of miRNA expression
were performed using human miRNA v2 arrays and
system v1.7 reagents (Agilent, Santa Clara, CA, USA).
Further details may be found in the Supplementary
materials and methods.
Protein mass spectrometry
Peptides from processed lysates [29] of cell pellets
were separated by capillary liquid chromatography
(LC) and analysed by tandem mass spectrometry
(MS/MS) using the RSLCnano system and LTQ-
Orbitrap Velos mass spectrometer (Thermo Scientific,
Waltham, MA, USA). The data search against the
IPI Human 3.87 database and label-free quantitation
(LFQ) were performed using MaxQuant 1.2.2.5 [30].
Further details may be found in the Supplementary
materials and methods.
Statistical analyses
Statistical analyses were performed using Prism
(GraphPad, La Jolla, CA, USA) with two-tailed
tests described in the text [31]. Mass spectrom-
etry data were analysed using R (OSX v2.15.1);
expression levels were log2 median-normalized and
analysed using t-tests, and p values converted to
false discovery rates using Benjamini–Hochberg
methodology [32].
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Results
MiRNA expression in breast NFs differs from that in
CAFs
We compared the miRNA profiles of breast NFs with
those of CAFs using two sources of cells: (i) fibrob-
lasts isolated from formalin-fixed, paraffin-embedded
(FFPE) tissue using laser micro-dissection (LMD); and
(ii) a tissue culture model in which breast fibrob-
lasts were combined with either non-transformed breast
epithelial cells or breast cancer epithelial cells.
To validate our LMD protocols, we first prepared
samples enriched for either epithelial cells or stro-
mal fibroblasts from tissue blocks of a single breast
cancer case [luminal A subtype, (ER+/her2−)] and
from matched normal breast tissue. Figure 1A shows
representative LMD sections; fibroblast-enriched sam-
ples are referred to as fibroblast-enriched stroma (F).
Tumour sections were stained for smooth muscle actin
(SMA), demonstrating that the majority of CAFs were
SMA-positive (Figure 1B). MiRNAs were extracted
from LMD samples and microarrays were used to
determine expression profiles. Of the 723 miRNAs
analysed, 229 (32%) were detected in at least one
sample. Many miRNAs were detected in fibroblast-
enriched stroma that were not detected in epithelial
cells from the same tissue (normal tissue: 86; can-
cer tissue: 68; Figure 1B), demonstrating that LMD
had successfully allowed enrichment for separate cell
populations and that the fibroblast-enriched stroma and
epithelial miRNA profiles differed. Very few epithelial-
specific miRNAs were identified (normal tissue: 3; can-
cer tissue: 7; Figure 1B). We then examined differential
expression between normal and cancer as determined in
fibroblast-enriched stroma or epithelial samples (Figure
1C). Seventy-six and 26 miRNAs were found to be
down- or up-regulated, respectively, in both epithelium
and fibroblast-enriched stroma, indicating some com-
monality between miRNA deregulation in these breast
cancer compartments. A large number of miRNAs
were found to be deregulated solely within fibroblast-
enriched stroma (77 down; 82 up), while epithelial
cell-specific deregulation was relatively rare (14 down;
16 up).
MiRNA expression was also examined in a tissue
culture model. Immortalized breast fibroblasts were
co-cultured with either HB2 cells, breast epithelial
cells of non-cancer origin considered to represent
normal epithelium, or MCF7 cells, representative of
epithelial cells of the most common breast cancer
subtype (luminal A). Epithelial cell lines were stably
labelled with GFP in order to allow their separate
analysis within co-cultures. Fibroblasts had a potent
and differential effect on the growth of the two
epithelial cell types; the growth of MCF7 cancer cells
was stimulated more than five-fold by fibroblasts, while
the growth of HB2 cells was not altered (Figure 2).
Thus, fibroblasts within the fibroblast/MCF7 co-culture
behaved in a manner analogous to CAFs [6], while
Figure 1. Laser micro-dissection (LMD) allowed analysis of miRNA
deregulation in the fibroblast and epithelial cell compartments
of breast cancers. (A) Representative images of breast cancer
tissue before (left) and after (right) LMD of fibroblast-enriched
stroma or epithelial cells as labelled. FFPE breast tissue was
sectioned and stained with toluidine blue. Regions for LMD were
identified based on morphology. (B) Representative images of
tumour sections stained for smooth muscle actin (SMA) using
immunohistochemistry. (C, D) Total RNA was extracted from at
least 5mm2 of LMD tissue enriched for fibroblasts or epithelial
cells from breast cancer tissue or from matched normal breast
tissue. Microarray analyses of miRNA expression were performed.
(C) Numbers of miRNAs detected in only samples of fibroblast-
enriched stroma (F), in both samples of fibroblast-enriched stroma
and epithelial cells (F and E), or in only epithelial cell samples
(E) are shown for each tissue. (D) Relative expression of each
miRNA was compared between normal and cancer tissue within
fibroblast-enriched stroma (F) or within epithelial cells (E). Numbers
of individual miRNAs that were up- or down-regulated in those
compartments are displayed in Venn diagrams showing how
many were deregulated in common between compartments (the
intersects), or were deregulated in one compartment only.
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Figure 2. Growth of MCF7 breast cancer epithelial cells, but
not non-transformed ‘normal’ HB2 breast epithelial cells, was
stimulated by immortalized breast fibroblasts. GFP-labelled MCF7
breast cancer cells (A) or HB2 benign breast epithelial cells (B)
were co-cultured with immortalized breast fibroblasts (pictured),
or were cultured alone, and epithelial cell growth was monitored by
counting GFP-positive cells using flow cytometry for up to 10 days.
Data are means of biological triplicates (± standard error) and are
representative of duplicate experiments.
those within the fibroblast/HB2 co-culture exhibited
less functional cross-talk. Fibroblasts were co-cultured
with HB2 or MCF7 cells for 9 days before being
isolated by fluorescence-activated cell sorting. MiRNA
expression within these fibroblasts was examined using
microarrays. Two hundred and twenty-six (31%) of
the 723 miRNAs analysed were detected in at least
one sample. One hundred and sixty-six miRNAs were
expressed at lower levels, and 60 miRNAs were more
highly expressed in the fibroblasts when they were
cultured with MCF7 cancer cells (the CAF model),
compared with those cultured with benign HB2 cells
(the NF model).
Next, we identified miRNAs that were consis-
tently differentially expressed both between NFs
and CAFs from clinical samples and between the
tissue culture model ‘NFs’ and ‘CAFs’ (complete
dataset—Supplementary Data 1). One hundred and
four miRNAs were down-regulated and ten miRNAs
were up-regulated in CAFs in both assays (see Sup-
plementary Data 2), representing a remarkably high
degree of overlap (eg 69% of LMD-identified down-
regulations were also seen in tissue culture, while 63%
of tissue culture-identified down-regulations were also
seen using LMD). Candidate miRNAs were further
filtered using a cut-off of fold changes greater than 10
in both assays, which left six miRNAs that showed
consistent and substantial down-regulation (Table 1).
MiR-26b is down-regulated in breast cancer CAFs
MiR-26b was examined further as it showed the
greatest mean fold change (Table 1). Further sam-
ples enriched for NFs or CAFs were prepared by
Table 1. Six miRNAs are consistently down-regulated more than
ten-fold in breast CAFs compared with breast NFs in both tissues
(comparing matched NF-enriched stroma and CAF-enriched
stroma prepared by LMD; Figure 1) and a co-culture model
[comparing immortalized breast fibroblasts co-cultured either
with the benign breast epithelial cell line HB2 (representing NFs)
or with the breast carcinoma cell line MCF7 (representing CAFs);
Figure 2]. ‘GeoMean fold change’ is the Geomean of the fold










MiR-7f Down 47.6 10.2 22
Let-7 g Down 15 11.4 13
MiR-107 Down 13.1 11.5 12.3
MiR-15b Down 14.2 10.8 12.4
MiR-26b Down 21 49.3 32.2
MiR-30b Down 12.3 30.2 19.3
LMD from archival tissue blocks representing an addi-
tional 14 sequential cases of luminal A subtype breast
cancers (defined as ER+/her2−). MiR-26b expres-
sion was quantified using qPCR (Figure 3A). MiR-26b
was down-regulated in CAF-enriched stroma compared
with NF-enriched stroma in 11/14 cases (Figure 3A;
Wilcoxon matched-pair signed rank p= 0.04). We also
examined miR-26b expression in matched primary cul-
tures of NFs and CAFs isolated from four more breast
cancer cases; miR-26b was down-regulated in CAFs
in all cases (Figure 3B). Therefore, we found miR-26b
to be down-regulated in CAFs in 15/18 cases in our
validation cohort. Supplementary Table 1 shows the
clinical features of this cohort.
Reduced miR-26b activity in fibroblasts inhibits
growth but enhances migration and invasion
We examined whether manipulation of miR-26b lev-
els resulted in changes in fibroblast behaviour. Firstly,
we transiently transfected immortalized breast fibrob-
lasts with anti-miR-26b or control molecules. We
used qPCR to assess the degrees of miR-26b knock-
down in these transfections. MiR-26b expression was
reduced by more than three-fold (Figure 4A; p= 0.03),
although it is worth noting that this may under-
represent the reduction in miR-26b function since
some miR-26b molecules detected may have been
functionally sequestered in the cells by anti-miR-26b
molecules. Transient knock-down of miR-26b caused a
small but statistically significant reduction in fibroblast
growth (Figure 4B; p= 0.02 at 48 h). We also mea-
sured the migration of anti-miR-26b or control trans-
fected fibroblasts using trans-well assays. Migration
was significantly increased by more than three-fold by
anti-miR-26b transfection (Figure 4C; p= 0.008). We
also investigated the consequences of miR-26b over-
expression by transiently transfecting fibroblasts with
pre-miR-26b or control molecules. MiR-26b overex-
pression caused dramatic and rapid cell death (Supple-
mentary Figure 1), as has been observed previously in
colorectal cancer cells [33]. However, qPCR analyses
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2013; 231: 388–399
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
392 ET Verghese et al
Figure 3. MiR-26b expression was frequently down-regulated in
CAFs compared with matched NFs. (A) Samples enriched for
fibroblasts were isolated by LMD from samples of matched breast
cancer and normal tissue from 14 sequential cases of luminal A
breast cancer (see Supplementary Table 1). (B) Primary cultures
of matched NFs and CAFs were established from four further
breast cancer cases. qPCR was used to analyse miR-26b expression
relative to the geometric mean RNU6B and RNU48. Data are means
of technical triplicates (± standard error).
revealed that miR-26b was overexpressed by more than
1000-fold in these transfections (Supplementary Figure
1C). We believe that this lacks clinical relevance since
this degree of overexpression greatly exceeded differ-
ential miR-26b expression in matched NFs and CAFs
(Figure 3); therefore, we did not proceed with further
overexpression studies.
To study the consequences of reduced miR-26b func-
tion, we stably knocked down miR-26b in breast fibrob-
lasts using lentiviral vectors (which also conferred
GFP expression). Fibroblasts were stably transduced to
reduce miR-26b function (designated ‘26bk/d’), or were
transduced with control virus (designated ‘controlk/d’),
and flow cytometry was used to enrich populations
to maintain more than 90% transduced cells (GFP-
positive). A two-fold reduction in miR-26b expres-
sion was observed by qPCR (Figure 5A; p= 0.02). As
before, we were conscious that this might not accu-
rately reflect functional knock-down; we therefore also
performed luciferase reporter assays to assess miR-26b
function. A single, fully complementary miR-26b bind-
ing site was cloned downstream of the luciferase read-
ing frame in a reporter, and 26bk/d or controlk/d cells
were transfected with the reporter. Luciferase assays
demonstrated that 26bk/d cells allowed two-fold higher
expression of a miR-26b target (Figure 5B; p= 0.001),
indicative of reduced miR-26b function. We also exam-
ined the influences of miR-26b knock-down on cell
growth/viability by both monitoring the growth of
26bk/d and controlk/d cells (Figure 5C) and examining
their cell cycle distributions (Figure 5D). In accordance
with our previous findings (Figure 4A), we found that
26bk/d cells grew slightly more slowly than controlk/d
cells (p= 0.01 at 72 h). This appeared to relate to a
cell cycle defect represented by an increase in cells in
the G2/M phase (Figure 5D; p= 0.02). However, these
growth and cell cycle defects are minor and may lack
biological relevance. Next, we examined the migra-
tory or invasive capacities of 26bk/d and controlk/d cells
using scratch-closure and trans-well migration assays,
or trans-well Matrigel invasion assays. 26bk/d cells
showed increased migration in scratch-closure assays,
although this fell just short of statistical significance
(Figure 5E; p= 0.06). However, 26bk/d cells demon-
strated significantly enhanced migration and invasion
in trans-well assays (Figure 5F, p= 0.001; Figure 5G,
p= 0.03). A second independent immortalized breast
Figure 4. Transient miR-26b down-regulation in breast fibroblasts inhibited growth but stimulated migration. Immortalized breast
fibroblasts were transiently transfected with anti-miR-26b molecules or with control anti-miRs. (A) MiR-26b expression was quantified
24 h after transfection using qPCR (relative to RNU6B). Data are means of technical triplicates (± standard error) and are representative
of duplicate experiments. (B) Cell growth was monitored by MTT assays over 72 h. (C) Migration of fibroblasts was assessed 24 h after
transfection using trans-well migration assays by manual counting of cells that had passed through the membranes. Data in B and C are
means of biological triplicates (± standard error) and are representative of duplicate experiments.
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Figure 5. Stable down-regulation of miR-26b in breast fibroblasts inhibited growth but stimulated both migration and invasion.
Immortalized breast fibroblasts were stably transduced to knock down miR-26b (26k/d) or with a control construct (conk/d). (A) MiR-26b
expression was quantified in the two cell lines using qPCR (relative to RNU6B). Data are means of technical triplicates (± standard error)
and are representative of duplicate experiments. (B) MiR-26b function was assessed as ratios of firefly to Renilla luciferase expression
using a miR-26b target luciferase reporter (containing a perfect miR-26b binding site downstream of firefly luciferase and also coding
for Renilla luciferase as an internal control). Cell lines were transfected with the reporter and dual luciferase assays were performed
after 24 h. (C) Cell growth in the two cell lines was monitored using MTT assays over 72 h after initial seeding of equal numbers of cells.
(D) Proportions of cells in G1, S, and G2/M phases of the cell cycle were determined in sub-confluent cultures using propidium iodide
staining and flow cytometry. (E) Migration was determined in scratch-closure assays using digital imaging as the percentage scratch area
remaining 18 h after scratch formation. Representative images are shown immediately after forming the scratch and at 18 h. (F) Migration
was determined in trans-well assays by manual counting of cells that had passed through the membrane. A representative example of the
trans-well migration result is shown. A second independent breast fibroblast line was also stably transduced (26k/d2 and conk/d2). Cells
having migrated through the membranes were counted at 12 h for 26k/d and conk/d and at 24 h for 26k/d2 and conk/d2 (the second pair of
transduced fibroblast lines migrated/invaded more slowly, reflecting variation between individual parental fibroblasts). (G) Invasion was
assessed using trans-well assays by manual counting (at the same time points as F). Data in B–G are means of biological triplicates (±
standard error) and are representative of duplicate (B, D–G) or triplicate (C) experiments.
fibroblast line was also transduced to knock down
miR-26b (designated ‘26bk/d2’) or was control trans-
duced (designated ‘controlk/d2’); this also demonstrated
significantly enhanced migration and invasion after
miR-26b knock-down (Figure 5F, p= 0.02; Figure 5G,
p= 0.02). We concluded that breast fibroblasts with
reduced miR-26b, as seen in CAFs, exhibited reduced
growth but increased motility and invasive capabilities.
Reduced miR-26b activity in fibroblasts enhances
migration/invasion of epithelial cancer cells
We were especially interested to determine whether
miR-26b in breast fibroblasts could modify epithelial
cancer cell behaviour. We co-cultured either 26bk/d or
controlk/d fibroblasts with MCF7 epithelial cancer cells.
We used MCF7 cells that stably express luciferase in
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Figure 6. MCF7 cell migration and invasion are stimulated by breast fibroblasts with reduced miR-26b. MCF7 cells (luciferase-positive)
were co-cultured with miR-26b knock-down (26k/d) or with control (conk/d) breast fibroblasts (seeding ratio of one epithelial cell to three
fibroblasts). (A) MCF7 cell growth was monitored within co-cultures using luciferase assays over 72 h (entire co-cultures were lysed and
luciferase activity, present within the epithelial cells only, was quantified). (B, C) Migration or invasion of MCF7 cells within co-cultures
was assessed 24 h after seeding in trans-well assays using luciferase assays (cells having passed through the membrane were lysed
and luciferase activity was quantified within the lysates). (D) MCF7 cells and fibroblasts were aggregated, forming three-dimensional
spheroids, and were suspended in a collagen-I/Matrigel matrix for up to 48 h. Invasion of MCF7 cells away from the central spheroid was
quantified as shown at 48 h. Assays were performed with 26k/d or conk/d fibroblasts and with equivalent lines derived from an independent
breast fibroblast line (line 2). (E, F) Spheroids were formalin-fixed and paraffin-embedded. Sections were taken and stained using
haematoxylin and eosin (E) or for epithelial cytokeratins (F). Scale bars (top right of each image)= 100µm. Epithelial cells (cobblestone
morphology/cytokeratin-positive) are labelled ‘e’, while populations of fibroblasts (elongated morphology/cytokeratin-negative) are labelled
‘f1’ (internal to spheroid outgrowth), ‘f2’ (surface of outgrowth), and ‘f3’ (within matrix radiating from spheroid). Data are means of at
least biological triplicates (± standard error) and are representative of duplicate (B–D) or triplicate (A) experiments.
order to quantify them separately within co-cultures.
As expected, the presence of fibroblasts enhanced
MCF7 growth (see Figure 2), but 26bk/d and controlk/d
fibroblasts did not have differential influences (Figure
6A). This experiment was performed seeding epithelial
cells and fibroblasts at a ratio of 1 : 3 in accordance
with published literature [6]; differential influences of
26bk/d and controlk/d fibroblasts on epithelial growth
were also not seen at other ratios (Supplementary
Figure 2). Next, migration and invasion assays were
performed with MCF7/fibroblast co-cultures (seeding
ratios of 1 : 3). In trans-well assays, MCF7 cells
demonstrated significantly enhanced migration in the
presence of 26bk/d fibroblasts (Figure 6B; p= 0.008),
although a trend for enhanced invasion fell short of
statistical significance (Figure 6C). This enhanced
migration of MCF7 cells was not reproduced when
the fibroblasts were seeded separately in the lower
chambers of the trans-wells (Supplementary Figure
3). Invasion assays were also performed using three-
dimensional spheroids, which better reflect in vivo
interactions between cells and the microenvironment
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[34]. MCF7 cells were aggregated with 26bk/d or
controlk/d fibroblasts, or with each of the second
pair of transduced fibroblasts, 26bk/d2 or controlk/d2,
before being encased in collagen-I/Matrigel matrix and
incubated for up to 48 h. Invasion into the matrix of
large groups of cells was dramatically enhanced by the
26bk/d fibroblasts (Figure 6D; p= 0.01) compared with
controls; indeed, these outgrowths were absent in the
presence of one control line. These striking outgrowths
were characterized in more detail by staining with
haematoxylin and eosin (Figure 6E) or for epithe-
lial cytokeratins (Figure 6F). Outgrowths contained
predominantly epithelial cells (based on morphology
and positive cytokeratin expression; labelled ‘e’)
with some internal fibroblasts (based on morphology
and/or negative cytokeratin expression; labelled ‘f1’).
Fibroblasts were mainly visible on the external surface
of outgrowths (labelled ‘f2’) and radiating through the
matrix from the spheroid (labelled ‘f3’).
MiR-26b regulates multiple molecular pathways in
breast fibroblasts
Our next aim was to determine the molecular path-
ways responsible for the altered behaviour of 26bk/d
fibroblasts. Initially, we identified potential direct
miR-26b targets using bioinformatics (TargetScan;
http://www.targetscan.org); these predictions suggested
that miR-26b might target more than 100 different tran-
scripts. In order to identify pathways altered in breast
fibroblasts, we carried out proteomic comparisons of
26bk/d and controlk/d fibroblasts. Label-free protein
mass spectrometry was performed on triplicate flasks
of both cell types (dataset—Supplementary Data 3).
As expected, expressions in the triplicates were highly
related, with mean Spearman’s rho coefficients for pair-
wise comparisons between triplicates of 0.83 and 0.85
for 26bk/d and controlk/d cells, respectively (p< 0.001).
We identified proteins that were significantly differen-
tially expressed between the lines. Three hundred and
sixty proteins (of a total of 3369 detected) were differ-
entially expressed (Student’s t-test; p< 0.05). When
multiple testing was taken into account using a false
discovery rate (FDR) threshold of 0.1, this was reduced
to 11 proteins (Table 2). In order to determine molec-
ular pathways that were deregulated in 26bk/d cells,
we subjected the protein lists to gene ontology analy-
ses (ToppGene Suite; http://toppgene.cchmc.org/). The
list of 360 proteins was significantly enriched for
genes involved in glycolysis and TCA cycle (nine
genes from 35 in the genome; p< 0.01) and in
cytoskeletal regulation by Rho GTPases (14 from 72;
p< 0.0001) (Supplementary Table 2). For identifica-
tion of potential direct miR-26b targets, we limited
our analyses to changes in expression identified at
an FDR of less than 0.1. We examined whether the
11 differentially expressed proteins were predicted
miR-26b targets and whether this correlated with up-
or down-regulation; up-regulation in 26bk/d cells was
expected for direct miR-26b targets. Five proteins were
Table 2. Proteins differentially expressed between controlk/d and
26k/d fibroblasts (false discovery rate< 0.1). Immortalized breast
fibroblasts were virally transduced to reduce expression of
miR-26b (26k/d) or were control transduced (controlk/d). Label-free
quantitative protein mass spectrometry was performed on
triplicate flasks of the two cell lines. Fold changes were calculated
using mean expression levels in triplicate controlk/d samples and
triplicate 26k/d samples












∗Fold changes are shown only when the protein was detected in both cell
lines–when it was not detected in either line, only the direction of deregulation
is indicated.
up-regulated in 26bk/d cells, three of which were pre-
dicted targets, while six were down-regulated, none of
which were predicted targets (Table 2). This distribu-
tion of predicted targets supports the conclusion that
these three predictions are true direct targets. These
are tankyrase 1 binding protein 1 (TNKS1BP1 ), cleav-
age and polyadenylation-specific factor 7 (CPSF7 ),
and collagen type XII alpha 1 (COL12A1 ). The func-
tional relevance of these three molecules was exam-
ined further by mining publicly available data. Expres-
sion data are available for 53 breast cancers from
which cancer stroma was isolated by LMD and stromal
mRNA expression levels were profiled using expres-
sion arrays [5]. We tested whether stromal expres-
sion of TNKS1BP1 , CPSF7 or COL12A1 was asso-
ciated with differences in time to recurrence. Expres-
sion was dichotomized using Receiver Operator Curve
(ROC) analysis in order to allow Kaplan–Meier anal-
yses of groups with high and low expression. For
each gene, high expression, as seen in 26bk/d cells,
was significantly associated with increased rates of
recurrence (Figure 7; log rank, TNKS1BP1 p= 0.002,
CPSF7 p= 0.007, COL12A1 p= 0.043), implicating
them, and by inference miR-26b, as stromal determi-
nants of breast cancer outcome.
Discussion
CAFs are known to differ from NFs in their expression
profiles and, consequently, in their behaviour and influ-
ences on epithelial cancer cells. However, the molec-
ular basis of these expression differences is poorly
understood, with signalling from cancer and other stro-
mal cells [35], as well as epigenetic deregulation [10],
implicated as key influences. We examined whether
miRNA expression differs substantially between NFs
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Figure 7. Stromal expression of inferred miR-26b targets predicts breast cancer recurrence. Correlations between high and low (as defined
using ROC analyses) stromal expression of TNKS1BP1, CPSF7 or COL12A1 and breast cancer recurrence were tested using Kaplan–Meier
analyses, using publicly available mRNA expression array data from laser capture micro-dissected stromal breast cancer tissue from 53
breast cancers [5], mined using the Oncomine platform (https://www.oncomine.org).
and CAFs and whether these differences regulate
fibroblast behaviour. We focused on miR-26b, since it
was deregulated (down-regulated in CAFs) to the great-
est extent in our screens (Table 1). Down-regulation
of miR-26b has been observed previously in various
cancers, including glioma [36], head/neck/oral cancer
[37], hepatocellular cancer [38], and breast cancer [39],
and has generally correlated with higher grade or more
aggressive cancer types. This conclusion is supported
by the fact that low miR-26b expression correlated sig-
nificantly with poor cancer survival in hepatocellular
carcinoma [38], and in breast cancer in our analysis
of publicly available miRNA expression data (Sup-
plementary Figure 4). It should be emphasized that
all of these studies analysed expression in cell pop-
ulations that included both cancer and stromal cells;
therefore it is not possible to be certain of the cell
type in which miR-26b is expressed and functional.
An exception to this is a recent analysis of miRNA
expression in six paired primary cultures of NFs and
CAFs from breast cancers, in which miR-26b was iden-
tified as down-regulated in CAFs [20], in accordance
with our findings, although it is important to note that
this study included no assessments of the function or
targets of miR-26b.
At least 14 different direct targets for miR-26b have
been suggested in the literature (see Supplementary
Table 3) in a range of other cell types and supported
by differing levels of proof. The vast majority of
these potential target proteins were not detected in our
proteomic analyses, but those that were showed no
evidence of significant differential expression between
26bk/d and controlk/d cells. This is compatible with the
suggestion that miR-26b targets multiple transcripts
and that these vary with cell type. We identified three
miR-26b targets in breast fibroblasts and established
that their expression in this compartment was signif-
icantly associated with survival from breast cancer
(Figure 7). These molecules are functionally diverse:
TNKS1BP1 is involved in telomere maintenance
[40]; CPSF7 regulates polyadenylation [41]; and
COL12A1 is an extracellular matrix component [42].
This diversity hints at the potential for miR-26b to
have broad-ranging influences on cellular physiology,
as has been seen with some other miRNAs [43].
Importantly in this context, we analysed downstream
effects of manipulating miR-26b at a wider proteome
level. We identified two significantly deregulated
pathways: glycolysis/TCA cycle; and cytoskeletal
regulation by Rho GTPases. For glycolysis/TCA, all
genes were up-regulated in 26bk/d fibroblasts and they
included enzymes that catalyse five of the nine main
steps of glycolysis. Similar up-regulation of glycolytic
enzymes has recently been reported in bladder cancer
stroma [44]. These observations are potentially com-
patible with the ‘reverse Warburg effect’, as described
by Lisanti and co-workers [45], in which CAFs carry
out aerobic glycolysis, thereby producing lactate and
pyruvate that are used, in part, by neighbouring cancer
cells. However, published work suggests that this
results in enhanced cancer cell growth [46], which
we did not find (Figure 6A), rather than the enhanced
cancer cell migration/invasion that we saw (Figures
6B–6F). With respect to the second pathway, the
influences of Rho GTPases on cytoskeletal dynamics
and cellular motility are well established [47]. Notably,
Rho signalling has been implicated in CAF-mediated
remodelling of the tumour microenvironment, leading
to enhanced invasion of cancer cells [48,49], a model
discussed further below.
We have shown that reduced miR-26b can enhance
breast fibroblast migration and invasion (Figures 4
and 5) and that this, in turn, can stimulate migra-
tion and invasion of epithelial cancer cells in the
context of epithelial/fibroblast co-cultures (Figure 6).
At least two models have been proposed to explain
this stromal–epithelial cross-talk. Firstly, fibroblasts
secrete soluble paracrine factors that stimulate epithe-
lial migration/invasion directly. Secondly, fibroblasts
modify the structural microenvironment, making it
more permissive for epithelial migration/invasion.
From our data, we believe that a soluble paracrine
factor that acts directly on the epithelial cells is
less likely, since we were unable to recapitulate
the influence of 26bk/d fibroblasts on epithelial cells
when the cells were physically separated in culture
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(Supplementary Figure 3). Therefore, our preferred
model is one that involves modification of the struc-
tural microenvironment. Potentially, enhanced epithe-
lial invasion could be a passive phenomenon where
epithelial invasion occurs simply by following the pas-
sage of fibroblasts through the matrix, making use of
the ‘holes’ that remain behind the fibroblasts; in this
case, fibroblasts would be simply removing the bar-
rier of the matrix that inhibits epithelial movement.
However, our data indicate that the fibroblasts’ influ-
ence is more complex. 26bk/d fibroblasts significantly
stimulated the migration of epithelial cells in trans-
wells lacking matrix, where there was no barrier for
the fibroblasts to remove and no matrix in which
fibroblasts could leave these ‘holes’ (Figure 6B). In
addition, controlk/d fibroblasts invaded from spheroids,
albeit to a lesser degree than 26bk/d fibroblasts, pre-
sumably leaving the ‘holes’ in the matrix, but epithe-
lial invasion was hardly detectable at all. We inter-
pret this to suggest that active stimulation of epithelial
migration/invasion through stimulatory modifications
to the matrix is a component of the 26bk/d fibrob-
lasts’ influence. Fibroblasts enhance the invasion of
squamous cell carcinoma cells in a similar way, with
both matrix ‘holes’ and fibroblast deposition of the
matrix components fibronectin and tenascin-C impli-
cated as potential stimulatory mediators of epithelial
invasion [49]. In this case, RhoA signalling in the
fibroblasts was found to be important for both hole
formation and matrix deposition [49], which correlates
with our observation of deregulation of the Rho path-
way. The roles of fibronectin and tenascin-C in stimu-
lating this migration/invasion remain to be fully eluci-
dated. COL12A1 presents a further candidate molecule
for roles in making the matrix permissive for migra-
tion/invasion as it is known to organize and stabilize
matrix fibrils of collagen type I [50], a main matrix
component in our spheroid assay. In addition, increased
COL12A1 expression has recently been noted at col-
orectal cancer invasive fronts, implicating COL12A1
in invasion [42].
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